Jason John Luke

87PUBLICATIONS

322CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyMolecular targetsHaematological tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (87)

Sort by Publication Date:

|Jul 02, 2026

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

|Feb 11, 2026

Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors.

John L Villano, Jason J Luke, Ricklie Julian

|Nov 26, 2025

Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors.

Benjamin T Cooper, Wade T Iams, David B Page

|Nov 03, 2025

IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.

David H Aggen, Meredith McKean, Jean H Hoffman-Censits

|Jun 15, 2025

Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma.

Rebekah E Dadey, Ruxuan Li, Jake Griner

|Jun 11, 2025

And… We're Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring.

Matthew K Nguyen, Jason J Luke

Pageof 15

Frequent Collaborators

12 joint publications

Riyue Bao

Diwakar Davar

Georgina V Long

Dirk Schadendorf

Paolo A Ascierto

Ryan C Augustin

Yuanyuan Zha

Alexander M M Eggermont

3 joint publications

Daniel J Olson

3 joint publications

Aung Naing

Frequent Collaborators

12 joint publications

Riyue Bao

8 joint publications

Diwakar Davar

5 joint publications

Georgina V Long

5 joint publications

Dirk Schadendorf